OBJECTIVE: Examine treatment adherence rates in pediatric eosinophilic gastrointestinal disorders (EGID). METHODS: Participants were children aged 2.5-18 years with eosinophilic esophagitis or eosinophilic gastroenteritis (EGE) and their caregivers. A multimethod, multi-informant assessment including parent report and electronic monitoring was utilized, with a 90% cut point for nonadherence. RESULTS: Medication nonadherence prevalence was 30%. Adherence frequency was 91% ± 14% (0-100%) per parent report and 100% ± 69% (0-194%) per electronic monitors. Tube-feeding adherence was 99% ± 3%. Food allergen exposures were less than 1 per 2 weeks, with 33% nonadherence prevalence. Patients with EGE and toddlers with both conditions demonstrated poorer medication adherence (p's < .05). Caregivers reported higher number of missed medication doses than food exposures (p < .05). CONCLUSIONS: The prevalence and range of nonadherence demonstrates that subsets of these patients are nonadherent. Adherence to treatment in EGID is complex and multifaceted, with nonadherence varying across treatments.
OBJECTIVE: Examine treatment adherence rates in pediatric eosinophilic gastrointestinal disorders (EGID). METHODS:Participants were children aged 2.5-18 years with eosinophilic esophagitis or eosinophilic gastroenteritis (EGE) and their caregivers. A multimethod, multi-informant assessment including parent report and electronic monitoring was utilized, with a 90% cut point for nonadherence. RESULTS: Medication nonadherence prevalence was 30%. Adherence frequency was 91% ± 14% (0-100%) per parent report and 100% ± 69% (0-194%) per electronic monitors. Tube-feeding adherence was 99% ± 3%. Food allergen exposures were less than 1 per 2 weeks, with 33% nonadherence prevalence. Patients with EGE and toddlers with both conditions demonstrated poorer medication adherence (p's < .05). Caregivers reported higher number of missed medication doses than food exposures (p < .05). CONCLUSIONS: The prevalence and range of nonadherence demonstrates that subsets of these patients are nonadherent. Adherence to treatment in EGID is complex and multifaceted, with nonadherence varying across treatments.
Authors: Chris A Liacouras; Glenn T Furuta; Ikuo Hirano; Dan Atkins; Stephen E Attwood; Peter A Bonis; A Wesley Burks; Mirna Chehade; Margaret H Collins; Evan S Dellon; Ranjan Dohil; Gary W Falk; Nirmala Gonsalves; Sandeep K Gupta; David A Katzka; Alfredo J Lucendo; Jonathan E Markowitz; Richard J Noel; Robert D Odze; Philip E Putnam; Joel E Richter; Yvonne Romero; Eduardo Ruchelli; Hugh A Sampson; Alain Schoepfer; Nicholas J Shaheen; Scott H Sicherer; Stuart Spechler; Jonathan M Spergel; Alex Straumann; Barry K Wershil; Marc E Rothenberg; Seema S Aceves Journal: J Allergy Clin Immunol Date: 2011-04-07 Impact factor: 10.793
Authors: Laurie J Bauman; Elizabeth Wright; Frederick E Leickly; Ellen Crain; Deanna Kruszon-Moran; Shari L Wade; Cynthia M Visness Journal: Pediatrics Date: 2002-07 Impact factor: 7.124
Authors: Benjamin F Sallis; Lena Erkert; Sherezade Moñino-Romero; Utkucan Acar; Rina Wu; Liza Konnikova; Willem S Lexmond; Matthew J Hamilton; W Augustine Dunn; Zsolt Szepfalusi; Jon A Vanderhoof; Scott B Snapper; Jerrold R Turner; Jeffrey D Goldsmith; Lisa A Spencer; Samuel Nurko; Edda Fiebiger Journal: J Allergy Clin Immunol Date: 2017-12-19 Impact factor: 10.793
Authors: Carol J Henderson; J Pablo Abonia; Eileen C King; Philip E Putnam; Margaret H Collins; James P Franciosi; Marc E Rothenberg Journal: J Allergy Clin Immunol Date: 2012-04-26 Impact factor: 10.793